



DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

Date: October 20, 2021

Time: 10:00am – 3:00pm (CST)

Location: Webex

[Join Webex Meeting](#)

Meeting number (access code): 177 575 2163

Meeting password: MMcyvnmS353

Join from a Video System/Application

Dial [1775752163@stateofmo.webex.com](tel:1775752163)

Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

| | | |
|---------------|--|---------------------|
| 10:00 – 10:05 | Welcome, Announcements and Introductions | Chairperson |
| 10:05 – 10:15 | Minutes Review | Discussion/Approval |
| 10:15 – 10:25 | Pharmacy Program/Budget Update | Elizabeth Short |
| 10:25 – 10:35 | Review of Prior Authorization Meeting and Public Hearing | Josh Moore |

Old Business

| | | |
|---------------|--|------------|
| 10:35 – 10:45 | Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's | Josh Moore |
|---------------|--|------------|

New Business

| | | |
|---------------|---|------------|
| 10:45 – 11:00 | Proposed Actions – New Drug/Product Review (See Website and Attached Summary) i. Open Access ii. Clinical Edit/Step Therapy iii. PDL Agents iv. Prior Authorization | Josh Moore |
|---------------|---|------------|

Clinical and Fiscal Edit Review

| | | |
|---------------|--|------------|
| 11:00 – 11:45 | <u>Existing Criteria</u> i. Emsam ii. Immunoglobulin iii. Lambert-Eaton Myasthenic Syndrome (LEMS) iv. Neuromyelitis Optica Spectrum Disorder (NMOSD) v. Nuedexta vi. Oxandrin vii. Palforzia viii. Ranexa ix. Xcopri | Josh Moore |
| | <u>New Criteria or Revision of Existing Criteria</u> x. Aduhelm xi. Botulinum Toxin xii. Equetro xiii. Narcolepsy Inhibitors xiv. Psychotropic Medications Polypharmacy xv. Selective Serotonin Reuptake Inhibitor (SSRI) | |

- xvi. Serotonin and Norepinephrine Reuptake Inhibitors (SNRI)
- xvii. Transthyretin-Mediated Amyloidosis (ATTR)

Preferred Drug List Edit Review

| | | |
|--------------|--|------------|
| 11:45 – 1:00 | <u>Existing Criteria</u> <ul style="list-style-type: none"> i. ARBs and ARBs/Diuretic Combinations ii. ARBs/CCB Combinations iii. Calcium Channel Blockers, Dihydropyridine iv. Calcium Channel Blockers, Non-Dihydropyridine v. Direct Renin Inhibitors and Combinations vi. Dry Eye Disease Agents vii. Niacin Derivatives viii. PAH, ETAs ix. PAH, Prostacyclins Inhaled x. PAH, Prostacyclins Oral xi. Sympatholytics <u>New Criteria or Revision of Existing Criteria</u> <ul style="list-style-type: none"> i. ACE Inhibitors and ACE Inhibitors/Diuretic Combinations ii. ACE Inhibitors/Calcium Channel Blocker Combinations iii. ADHD, Amphetamines Long Acting iv. ADHD, Amphetamines, Short Acting v. ADHD, Methylphenidate Long Acting vi. ADHD, Methylphenidate, Short Acting vii. ADHD, Non-Stimulants viii. Anticoagulants ix. Anticonvulsants, Rescue Agents x. Antiplatelets xi. Beta Blockers and Beta Blockers/Diuretic Combinations xii. PAH, PDE5/SGC Stimulators xiii. PAH, Prostacyclins Injectable xiv. PCSK9 Inhibitors xv. Proton Pump Inhibitors xvi. Statins (HMG-CoA Reductase Inhibitors) and Combinations xvii. Triglyceride Lowering Agents | Josh Moore |
|--------------|--|------------|

Break

1:00 – 1:15 Lunch

Program Utilization Information – Conduent Update

| | | |
|-------------|--|------------------|
| 1:15 – 1:30 | Reports <ul style="list-style-type: none"> i. Call Center Statistics ii. New Drug Statistics iii. “Top 25” Drugs by Cost/Claims | Jennifer Colozza |
|-------------|--|------------------|

Other Business/Closing Comments

1:30 – 1:50 Other Business

Executive Session

2:00 – 3:00 Patient Profile Reviews

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, agenda may move more quickly.*

NEXT MEETING: January 19, 2022

***Subject to change: Beginning October 2021, the Drug Prior Authorization Committee (DPAC) and Drug Utilization Review (DUR) meetings will allow in-person attendance for board members and associated MO HealthNet staff only. Webex will remain available for all other attendees.**

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*